Beckman Coulter expands flow cytometry portfolio
This article was originally published in Clinica
Executive Summary
Beckman Coulter Life Sciences has acquired the flow cytometry business of ReaMetrix India, a Bangalore-based life science technology company. ReaMetrix was among the first to bring to the market dry, room temperature-stable reagents for in vitro diagnostic use, according to Beckman Coulter. The products, which are CE-marked but not yet cleared by the US FDA, are used for routine clinical analyses, specifically HIV monitoring and clinical research, two key flow cytometry market segments. They help to “simplify the sample preparation process” and in turn increase productivity of cytometrists, and will enable to broaden Beckman’s existing flow cytometry offerings.
You may also be interested in...
Could Alcon's CyPass Trouble Be Boon For Glaukos – Or Bust For MIGS?
Minimally invasive glaucoma surgery specialist Glaukos saw its stock leap 40% in the wake of a worldwide recall by much bigger rival Alcon of its CyPass microstent.
Roche Dx' EMEA Head To Take Charge After Diggelmann Departs
Roland Diggelmann will end his decade-long career at Roche Diagnostics at the end of September. The business's head of EMEA Michael Heuer will take Diggelmann's place while the search is on for his replacement.
Nose For A Good Tech? Philips Adds Nasal Alar Pulse Oximetry To Monitoring Portfolio
Philips has added a new pulse oximetry platform to its patient monitoring portfolio, with the acquisition of Xhale Assurance.